Physician profile
Seth Matarasso
NPI 1992882948
$43,765.85
in general payments reported to CMS, 2019-2025
17 companies · $5,945 in 2025
The $5,945 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,458 · 2020: $15K · 2021: $761 · 2022: $1,796 · 2023: $3,742 · 2024: $7,462 · 2025: $5,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $2,967 · Gift: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,010.83 |
| Food and Beverage | $2,966.96 |
| Gift | $170.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19,675.22 | 2019-2022 | |
| Abbvie INC. | $16,201.45 | 2023-2025 | |
| Galderma Laboratories, L.P. | $4,426.94 | 2019-2024 | |
| Merz North America, INC. | $2,616.43 | 2019-2025 | |
| Pfizer INC. | $274.68 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $118.85 | 2022 | |
| Genzyme Corporation | $104.02 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Lilly USA, LLC | $58.07 | 2021-2022 | |
| Biofrontera INC. | $53.69 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $53.52 | 2022-2023 | Simponi, Simponi Aria, Stelara |
| Solta Medical, A Division of Bausch Health US, LLC | $24.54 | 2021 | |
| Mayne Pharma Commercial LLC | $24.02 | 2019 | |
| Amgen INC. | $22.11 | 2023 | Otezla |
| Incyte Corporation | $17.83 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.71 | 2020 | |
| Organon LLC | $9.20 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Matarasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.